Clinical Edge Journal Scan

Fertility preservation safe in young women with BC


 

Key clinical point: Women who were diagnosed with breast cancer (BC) at a young age and underwent fertility preservation (FP) did not experience any increased risk for disease-specific mortality or relapse.

Major finding: Compared with women who did not undergo FP, disease-specific mortality was similar in women who underwent hormonal FP (adjusted hazard ratio [aHR] 0.59; 95% CI 0.32-1.09) and nonhormonal FP (aHR 0.51; 95% CI 0.20-1.29). Hormonal (aHR 0.81; 95% CI 0.49-1.37) and nonhormonal (aHR 0.75; 95% CI 0.35-1.62) FP were associated with similar relapse or death rates in a subcohort of 723 women with complete relapse information.

Study details : Findings are from an analysis of a population-based nationwide cohort study including 1275 women of reproductive age (18-44 years old) who were diagnosed with BC, of which 425 women received hormonal (n = 367) or nonhormonal (n = 58) FP treatment.

Disclosures: This study was supported by the Swedish Cancer Society and other sources. Prof. Bergh declared receiving grants and personal fees from several sources.

Source: Marklund A et al. Relapse rates and disease-specific mortality following procedures for fertility preservation at time of breast cancer diagnosis. JAMA Oncol. 2022 (Aug 25). Doi: 10.1001/jamaoncol.2022.3677

Recommended Reading

FDA warns of cancer risk in scar tissue around breast implants
Breast Cancer ICYMI
Single Institution Retrospective Review of Patterns of Care and Disease Presentation in Female Veterans With Breast Cancer During the COVID-19 Pandemic
Breast Cancer ICYMI
Time to cancer diagnoses in U.S. averages 5 months
Breast Cancer ICYMI
De-escalation of locoregional radiotherapy after primary chemotherapy appears safe in cT1-2N1 BC
Breast Cancer ICYMI
Sacituzumab govitecan bests chemotherapy in HR+/HER2− advanced BC
Breast Cancer ICYMI
Early TNBC: Durvalumab+NACT improves survival despite modest pCR increase
Breast Cancer ICYMI
Neratinib alone or in combination with capecitabine beneficial for advanced HER2+ BC
Breast Cancer ICYMI
Reassuring survival outcomes with trastuzumab+lapatinib in small and node-negative HER2+ BC
Breast Cancer ICYMI
Risk for brain metastasis highest with ERBB2+ and triple-negative metastatic BC
Breast Cancer ICYMI
ER+/HER2+ BC: HER2-enriched subtype predicts poor response to AI therapy
Breast Cancer ICYMI